Health Trials

Merkel Cell Carcinoma of Skin

3

Review clinical trials related to Merkel Cell Carcinoma of Skin. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Participants needed: 21
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kupando GmbHUpdated: May 20, 2026Locations: 2
Eligibility criteria

Histologically confirmed cancer with evidence of advanced disease for which no o... [+2]

Previous systemic treatment with TLR agonists, with the exception of TLR agonist... [+10]

Read more
Status: Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: KaliVir ImmunotherapeuticsUpdated: Apr 7, 2026Locations: 7
Eligibility criteria

Have pathologically confirmed, advanced, unresectable, or metastatic solid tumor... [+6]

Prior systemic therapy washout (dependent upon the therapy) [+5]

Read more
Status: Recruiting

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Participants needed: 15
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Nov 19, 2025Locations: 1
Eligibility criteria

Patients >= 18 years old; [+3]

Patients ongoing another interventional clinical trial; [+3]

Read more